The company added AEOL 10150 is being developed as a treatment for the lung and delayed effects of acute radiation exposure
(Lung-ARS) under a USD118.
Two treatment conditions were used throughout the experiments: a) continuous low dose-rate radiation, and b) acute radiation exposure
A new class of pharmaceutical that promises to protect patients from acute radiation exposure
has been developed.
Note that one must be exposed to something in the area of 100,000 mrems of radiation in a short period to suffer symptoms of acute radiation exposure
, and even more than that to risk death.
In the aftermath of the nuclear meltdown at Chernobyl, 56 people died from acute radiation exposure
According to the company, its lead compound, AEOL 10150, is being developed for the treatment of pulmonary syndrome of Acute Radiation Syndrome (Lung-ARS) and delayed effects of acute radiation exposure
(DEARE) under a contract with BARDA.
According to the company, AEOL 10150 is being developed for cancer patients receiving radiation therapy and for the pulmonary and delayed effects of acute radiation exposure
under a five-year contract with the Biomedical Advanced Research and Development Authority, a division of the US Department of Health and Human Services.
M2 EQUITYBITES-January 24, 2014-Aeolus Pharmaceuticals Inc wins US FDA's Orphan Drug Designation for AEOL 10150 to treat patients exposed to acute radiation exposure
M2 PHARMA-January 24, 2014-Aeolus Pharmaceuticals Inc wins US FDA's Orphan Drug Designation for AEOL 10150 to treat patients exposed to acute radiation exposure